SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$34.38 USD
-0.97 (-2.74%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $34.38 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Brokerage Reports
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 1 - 20 ( 201 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
OGSIVEO Tops Estimates Again; Raising PT to $76
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
ReNeu Trial Results Consistent With Prior Release; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
TEAD Inhibitor SW-682 Implications From Recent Developments; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
OGSIVEO 1Q24 Sales Top Consensus Estimates; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Making Mature Progress on Multiple Fronts; Modulating PT to $74
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Mirdametinib Rolling Towards the NF1-PN Market
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D